Roche to buy intestinal disease drug from Roivant and Pfizer for more than $7 billion

Roche to buy intestinal disease drug from Roivant and Pfizer for more than $7 billion


Updated October 23, 2023 at 6:55 a.m. ET

rock Holding has agreed to buy the developer of a treatment for intestinal diseases from Roivant Sciencesa company created by the Republican presidential candidate Vivek RamaswamyAnd Pfizer in a deal worth more than $7 billion.

The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings and make a near-term milestone payment of $150 million. Roche said the deal gives it the right to commercialize Telavant’s drug candidate RVT-3101, which has shown promise in treating inflammatory bowel disease and may have potential in other indications, including: United States and Japan.

Copyright ©2023 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8



With a penchant for words, Eleon Smith began writing at an early age. As editor-in-chief of his high school newspaper, he honed his skills telling impactful stories. Smith went on to study journalism at Columbia University, where he graduated top of his class. After interning at the New York Times, Smith landed a role as a news writer. Over the past decade, he has covered major events like presidential elections and natural disasters. His ability to craft compelling narratives that capture the human experience has earned him acclaim. Though writing is his passion, Eleon also enjoys hiking, cooking and reading historical fiction in his free time. With an eye for detail and knack for storytelling, he continues making his mark at the forefront of journalism.
Back to top button